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HOX transcription factors are potential
targets and markers in malignant
mesothelioma
Richard Morgan1*, Guy Simpson2, Sophie Gray2, Cheryl Gillett3, Zsuzsanna Tabi4, James Spicer3,
Kevin J. Harrington5 and Hardev S. Pandha2
Abstract
Background: The HOX genes are a family of homeodomain-containing transcription factors that determine cellular
identity during development and which are dys-regulated in some cancers. In this study we examined the
expression and oncogenic function of HOX genes in mesothelioma, a cancer arising from the pleura or peritoneum
which is associated with exposure to asbestos.
Methods: We tested the sensitivity of the mesothelioma-derived lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-
H226 to HXR9, a peptide antagonist of HOX protein binding to its PBX co-factor. Apoptosis was measured using a
FACS-based assay with Annexin, and HOX gene expression profiles were established using RT-QPCR on RNA
extracted from cell lines and primary mesotheliomas. The in vivo efficacy of HXR9 was tested in a mouse MSTO-
211H flank tumor xenograft model.
Results: We show that HOX genes are significantly dysregulated in malignant mesothelioma. Targeting HOX genes
with HXR9 caused apoptotic cell death in all of the mesothelioma-derived cell lines, and prevented the growth of
mesothelioma tumors in a mouse xenograft model. Furthermore, the sensitivity of these lines to HXR9 correlated
with the relative expression of HOX genes that have either an oncogenic or tumor suppressive function in cancer.
The analysis of HOX expression in primary mesothelioma tumors indicated that these cells could also be sensitive to
the disruption of HOX activity by HXR9, and that the expression of HOXB4 is strongly associated with overall
survival.
Conclusion: HOX genes are a potential therapeutic target in mesothelioma, and HOXB4 expression correlates with
overall survival.
Keywords: Mesothelioma, HOX genes, HXR9, HOXB4, Overall survival
Background
The HOX genes are a family of transcription factors char-
acterized by highly conserved DNA- and co-factor binding
domains. This conservation has been driven by their roles
in some of the most fundamental patterning events that
underlie early development [1]. Most notable of these is
the patterning of the anterior to posterior axis, for which a
precise spatial and temporal order in the expression of
HOX genes is required. This is achieved in part through a
chromosomal arrangement whereby HOX genes are
present in closely linked clusters allowing the sharing of
common enhancer regions. In mammals there are four
such clusters (A–D), containing a total of 39 HOX genes
[1]. The relative position of each HOX gene 3′ to 5′ within
the cluster is reflected in a number of key attributes, in-
cluding the spatial and temporal order of expression,
whereby the 3′ most genes are expressed earlier than their
5′ neighbors. The nomenclature of the HOX genes
reflects this precise chromosomal ordering, with mem-
bers of each cluster being numbered with respect to the
3′ end, thus for example, the 3′ most member of clus-
ter B is HOXB1 [2].
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The 3′ to 5′ order of HOX genes is reflected not only
in their expression patterns but also in their DNA bind-
ing specificities and co-factor interactions. For example,
the products of the 3′ HOX genes (1 to 9) bind to an-
other transcription factor, PBX, which modifies their
binding specificity to DNA [3], influences their nucleo-
cytoplasmic distribution [3], and also determines
whether a HOX protein will activate of repress tran-
scription of downstream target genes [4]. This inter-
action with PBX is mediated through a highly conserved
hexapeptide region on HOX proteins 1–9 that binds to a
cleft in PBX [3, 5]. Once PBX has bound it can recruit
other specific co-factors, including MEIS, which can
then further modify HOX activity [6].
Although HOX genes were initially characterized as
key developmental genes, they also function in adult
stem cells to promote proliferation [7], and subsequently
in their progeny to confer lineage-specific identities [8].
Furthermore, HOX genes are strongly dys-regulated in
cancer, and generally exhibit greatly increased expres-
sion. This differential change in expression in cancer may
reflect the apparent ability of some HOX genes to function
as tumor suppressors and some as oncogenes. Thus for
example, HOXA5 acts as a tumor suppressor in breast
cancer by stabilizing P53 [9], whilst forced expression of
HOXB6 can immortalize fibroblast cells [10]. Further ex-
amples of this phenomenon are listed in Table 1.
The dys-regulation of HOX genes has been demon-
strated in a range of cancers, and in some it has been
shown to be a potential therapeutic target through the
use of a peptide, HXR9. HXR9 prevents PBX binding to
HOX and triggers apoptosis in malignant cells, whilst
sparing normal adult cells [11–17]. Although these stud-
ies include non-small cell lung cancer (NSCLC) [16],
they do not encompass mesothelioma, a malignancy of
the mesothelium cells which is most frequently found in
the lung and is associated with long term exposure to
asbestos [18]. Mesothelioma has limited treatment op-
tions and generally a very poor prognosis [18], and
therefore finding novel therapeutic approaches in this
disease is an important goal. In this study we show that
HOX dys-regulation is present in cell lines derived from
mesothelioma, and in primary tumors, usually with a
significant increase in the expression of those HOX
genes that behave as oncogenes. Furthermore, antagon-
ism of the HOX / PBX interaction in these cell lines
triggers apoptosis, with malignant cells generally being
considerably more sensitive to HXR9 than cells derived
from non-malignant mesothelium cells.
Methods
Cell lines and culture
The cell lines used in this study are listed in Table 2.
They were obtained from the ATCC through LGC
Standards Ltd (UK), and were cultured according to the
instructions on the LGC Standards website.
Synthesis of HXR9 and CXR9 peptides
HXR9 is an 18 amino acid peptide consisting of the pre-
viously identified hexapeptide sequence that can bind to
PBX and nine C-terminal arginine residues (R9) that
facilitate cell entry. The N-terminal and C-terminal
amino bonds are in the D-isomer conformation,
which has previously been shown to extend the half-
life of the peptide to 12 h in human serum [14].
CXR9 is a control peptide that lacks a functional
hexapeptide sequence but which includes the R9
sequence. The sequences of these peptides have been
published previously [13]. All peptides were synthe-
sized using conventional column based chemistry and
purified to at least 80 % (Biosynthesis Inc., USA).
Imaging of cell cultures
Cells were plated in 6-well plates using 2 ml of medium
and allowed to recover for at least 24 h. When approxi-
mately 60 % confluent, cells were treated with the active
peptide HXR9 (60 μM) or the control peptide CXR9
(60 μM) for 3 h.
Table 1 HOX genes with potential oncogenic or tumor
suppressor functions
Gene O / S Evidence Reference
HOXA1 O Transforms non-malignant
mammary epithelial cells
[28]
HOXA9 O Key oncogene in leukemia [29]
HOXB3 O Pro-survival and proliferation
gene in leukemia
[29]
HOXB4 O Pro-survival and proliferation
gene in leukemia
[29]
HOXB5 O Transfection can immortalize
fibroblast cells
[21]
HOXB6 O Transfection can immortalize
myelomonocytic cells
[10]
HOXB9 O Promotes tumorogenesis in
breast cancer
[30]
HOXC4 O High expression in malignant
prostate cells
[31]
HOXA4 S Blocks spread of ovarian cancer
cells
[32]
HOXA5 S Identified as a tumor suppressor
gene in breast ca
[9]
HOXC8 S Expression inversely related to
progression
[33]
HOXC12 S Promotes cell differentiation in
follicular lymphoma
[22]
HOXD12 S Silenced in melanoma cells [23]
O HOX gene with oncogenic activity, S HOX gene with tumor
suppressor activity
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Immunohistochemistry for HOXA4, HOXA9, and HOXB4
Expression of HOXA4, HOXA9, and HOXB4 in meso-
thelioma and normal mesothelium tissue was investigated
using 3 μm-thick, formalin fixed, paraffin embedded tissue
array sections (MS081, US Biomax, Rockville, MD, USA).
Immunohistochemical analysis was performed using a
monoclonal rabbit anti-HOXB4 antibody (ab676093,
1:100 dilution, Abcam, Cambridge, UK), a polyclonal
rabbit anti-HOXA4 antibody (ab131049, 1:500 dilution,
Abcam, Cambridge, UK), and a polyclonal rabbit anti-
HOXA9 antibody (ab191178, 1:75 dilution, Abcam,
Cambridge, UK). The ABC detection method with per-
oxidase block (DakoCytomation) was used for all of
these primary antibodies. Antigen retrieval was performed
using pH 9.0 Tris/EDTA buffer (DakoCytomation) and
heating in a microwave for 23 min.
Analysis of cell death and apoptosis
Cells were treated with HXR9 or CXR9 as described
above. Cell viability was assessed using the MTS assay
(Promega) according to the manufacturer’s instructions.
Cells were harvested by incubating in trypsin-EDTA
(Sigma) at 37 °C until detached and dissociated. Apoptotic
cells were identified using flow cytometry (Beckman
Coulter Epics XL Flow) and the Annexin V-PE apoptosis
detection kit (BD Pharmingen) as described by the manu-
facturer’s protocol. Caspase-3 activity was measured using
the EnzCheck Caspase-3 Assay Kit (Molecular Probes),
using the protocol defined by the manufacturer.
RNA purification and reverse transcription
Total RNA was isolated from cells using the RNeasy
Plus Mini Kit (Qiagen) by following the manufacturer’s
protocol. The RNA was denatured by heating to 65 °C
for 5 min. cDNA was synthesized from RNA using the
Cloned AMV First Strand Synthesis Kit (Invitrogen)
according to the manufacturer’s instructions.
Quantitative PCR
Quantitative PCR was performed using the Stratagene
MX3005P real-time PCR machine and the Brilliant SYBR
Green QPCR Master Mix (Stratagene). The following
primers were designed to facilitate the unique amplifica-
tion of β-actin, c-Fos, and each HOX gene:
HsBeta-ActinF: 5′ ATGTACCCTGGCATTGCCGAC 3′
HsBeta-ActinR: 5′ GACTCGTCATACTCCTGCTTG 3′
HscFos1F: 5′ CCAACCTGCTGAAGGAGAAG 3′
HscFos1R: 5′ GCTGCTGATGCTCTTGACAG 3′
HsHOXA1F: 5′ CTGGCCCTGGCTACGTATAA 3′
HsHOXA1R: 5′ TCCAACTTTCCCTGTTTTGG 3′
HsHOXA4F: 5′ CCCTGGATGAAGAAGATCCA 3′
HsHOXA4R: 5′ AATTGGAGGATCGCATCTTG 3′
HsHOXA5F: 5′ CCGGAGAATGAAGTGGAAAA 3′
HsHOXA5R: 5′ ACGAGAACAGGGCTTCTTCA 3′
HsHOXA9F: 5′ AATAACCCAGCAGCCAACTG 3′
HsHOXA9R: 5′ ATTTTCATCCTGCGGTTCTG 3′
HsHOXB3F: 5′ TATGGCCTCAACCACCTTTC 3′
HsHOXB3R: 5′ AAGCCTGGGTACCACCTTCT 3′
HsHOXB4F: 5′ TCTTGGAGCTGGAGAAGGAA 3′
HsHOXB4R: 5′ GTTGGGCAACTTGTGGTCTT 3′
HsHOXB5F: 5′ AAGGCCTGGTCTGGGAGTAT 3′
HsHOXB5R: 5′ GCATCCACTCGCTCACTACA 3′
HsHOXB6F: 5′ ATTTCCTTCTGGCCCTCACT 3′
HsHOXB6R: 5′ GGAAGGTGGAGTTCACGAAA 3′
HsHOXB9F: 5′ TAATCAAAGACCCGGCTACG 3′
HsHOXB9R: 5′ CTACGGTCCCTGGTGAGGTA 3′
HsHOXC4F: 5′ CGCTCGAGGACAGCCTATAC 3′
HsHOXC4R: 5′ GCTCTGGGAGTGGTCTTCAG 3′
HsHOXC8F: 5′ CTCAGGCTACCAGCAGAACC 3′
HsHOXC8R: 5′ TTGGCGGAGGATTTACAGTC 3′
Mice and in vivo trial
All animal experiments were conducted in accordance with
the United Kingdom Coordinating Committee on Cancer
Research guidelines for the Welfare of Animals in Experi-
mental Neoplasia and were approved by the University of
Surrey Research Ethics Committee. The mice were kept in
positive pressure isolators in 12 h light / dark cycles and
food and water were available ad libitum.
Athymic nude mice were inoculated subcutaneously
with a suspension of 2.5 × 106 MSTO-211H cells in cul-
ture media (100 μl). Once tumors reached volumes of
approximately 100 mm3, mice were injected IP with PBS
or 25 mg/Kg HXR9 in PBS (injection volume 100 μl),
every 4 days. The mice were sacrificed after 36 days and
the tumors were excised for RNA extraction, as previ-
ously described [12]. Each treatment group contained
Table 2 Mesothelioma-derived cell lines used in this study
Cell line Source IC50 HXR9
(μM)
Ref
Met-5a Normal mesothelium cells
from pleural fluid
98 [34]
NCI-H28 Pleural effusion 18 ATCC
MSTO-211H Biphasic mesothelioma
(fibroblast morphology)
28 [35]
NCI-H2052 Pleural effusion
(epithelial morphology)
45 ATCC
NCI-H226 Squamous carcinoma;
mesothelioma
(epithelial morphology).
This cell line was derived
from non-small cell lung
cancer, although it was
subsequently found to
have a number of
mesothelioma-related
properties, including the
expression of mesothelin.
107 ATCC, [36]
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ten mice. The mice were monitored carefully for signs of
distress, including behavioral changes and weight loss.
Patient characteristics
Primary mesothelioma samples were obtained from 16
male and five female patients. The median patient age at
diagnosis was 63.9 years (range, 38.2–79.53 years) and me-
dian survival was 9.04 months (range, 0.23–81.85 months).
Recruitment was via a specialized multidisciplinary thor-
acic oncology clinic, involving thoracic surgeons, radiation
oncologists, and medical oncologists. Histopathology and
imaging review was undertaken for all patients. Patients
underwent tumor resection at the Department of Thoracic
Surgery, Guy’s & St Thomas’ NHS Foundation Trust.
Tumor samples were confirmed as mesothelioma by
pathological examination and categorized as a sarcoma-
toid, biphasic, or epithelial type using an antibody panel
that included BerEP4, CEA, TTF1, Calretinin, WT1, CK5,
MNF116, and EMA. Pseudoanonymised tissues and data
were collected by the KHP Cancer Biobank, and subse-
quently released for this study in accordance with NHS
REC approval number 07/H0804/91. Written informed
consent was obtained from patients when they agreed to
their tissue samples being included in the Biobank, it was
not required for the specific use of these tissues in this
project.
Statistical analysis
All values are given as the mean of three independent
experiments and error bars show the standard error of
the mean. Categorical variables were compared using
Student’s t-test or a one-way ANOVA. Survival curves
were generated using the Kaplan-Meier method and
compared using the log-rank test. A p value < 0.05 was
considered to be significant.
Results
HOX gene expression in mesothelioma-derived cell lines
and primary tumors
In order to assess the expression of HOX genes in meso-
thelioma we used QPCR to measure RNA levels in four
cell lines derived from this malignancy: NCI-H28, NCI-
H2052, NCI-H226, and MSTO-211H, together with
Met-5A which is derived from non-malignant mesothe-
lium cells (Table 2). HOX gene expression was also stud-
ied in primary mesothelioma tumors. The expression of
HOX genes within each cell line and between cell lines
varied considerably, with MSTO-211H and Met-5A gen-
erally having far higher expression than the other cell
lines. The only HOX genes expressed uniquely by a sin-
gle cell line were HOXC12 and HOXD12, in Met-5A.
Analysis of HOX genes that are known to have onco-
genic or tumor suppressive functions (Table 1) likewise
reveals considerable variation, although Met-5A showed
higher expression of the potential tumor suppressor
genes HOXA4 and HOXA5 compared to the malignant
cell lines (Fig. 1a). We also assessed the expression of
these HOX genes in 21 primary tumors using RT-QPCR,
as well the protein expression of the three most strongly
expressed, HOXA4, HOXA9, and HOXB4 at the protein
level using immunohistochemistry (Fig. 1b).
High HOXB4 tumor expression is associated with poor
overall survival
We looked for associations between the RNA expres-
sion levels of the different HOX genes and patient
survival. The tumors of patients surviving less than
6 months had a significantly higher expression of
HOXB4 (p = 0.0166; Fig. 1c), and likewise a Kaplan-
Meier analysis of overall survival (OS) showed that
high HOXB4 tumor expression was associated with a
significantly shorter OS (p = 0.041; Fig. 1d).
HXR9 is cytotoxic to mesothelioma cells
Given the high level of HOX expression in the mesotheli-
oma cell lines, we treated cells with the HOX / PBX
inhibitor HXR9 that has previously been shown to block
HOX / PBX interactions and trigger apoptosis in a num-
ber of other cancers [11–17]. Use of a fluorescently la-
beled version of HXR9 demonstrated that it can be taken
up by the cell lines studied here (Fig. 2a), and the MTS
assay for cell viability revealed that HXR9 is cytotoxic in
all five cell lines (Fig. 2b,c; Table 2). The non-malignant
line Met-5A is amongst the least sensitive with an IC50 of
98 μM, whilst the NCI-H28 cell line is the most sensitive
with an IC50 of 18 μM (Fig. 2c, Table 2).
HXR9 triggers apoptosis
Previous studies have suggested that the mechanism of
cell death when HOX function is blocked by HXR9 is
primarily through apoptosis [11–17]. To establish
whether this is also the case of the mesothelioma derived
cell lines, a standard FACS based assay for apoptosis-
associated cell membrane changes was used. This in-
volves the use of Annexin V that binds to membrane
components usually located on the cytoplasmic side but
which relocate to the external surface during apoptosis
[19], and a fluorescent dye (7AAD) which binds to DNA
but can only enter cells when membrane integrity has
been lost. This assay revealed that all the mesothelioma
cell lines underwent apoptosis when treated with HXR9
at the relevant IC50 (Fig. 3), with the non-malignant cell
line Met-5A showing the lowest level of apoptosis and
NCI-H2052 the highest (Fig. 3c).
The induction of apoptosis by HXR9 is thought to
depend, at least in part, upon a rapid increase in cFos
expression [14], and QPCR analysis of the HXR9 treated
cells correspondingly showed a significant increase in
Morgan et al. BMC Cancer  (2016) 16:85 Page 4 of 11
Tumor suppresorsOncogenes
RNA expression by RT-QPCT
RNA expression by RT-QPCT
R
el
at
iv
e 
ex
pr
es
si
on
IHC
Neg
p 
=
 0
.0
16
6
dc
b
a
R
el
at
iv
e 
ex
pr
es
si
on
Fig. 1 (See legend on next page.)
Morgan et al. BMC Cancer  (2016) 16:85 Page 5 of 11
(See figure on previous page.)
Fig. 1 Expression of HOX genes in cell lines derived from mesothelioma (a) and (b) primary mesothelioma tumors. These genes were previously
shown to function as either oncogenes or tumor suppressors (see Table 1 for more detail). The relative levels of RNA for each gene are shown as
a ratio with Beta-actin (×10000 for NCI-H28, NCI-H2052 and NCI-H226, ×100 for primary mesothelioma tumors, Met-5A, and MSTO-211). For the cell
lines (a) each value is the mean of three experiments, and error bars show the SEM. For the primary tumors (b) the expression of each HOX gene is
shown for each individual tumor. The values shown are the mean of three technical repeats. No error bars are included in order to simplify the figure,
although all repeats were within 10 % of the mean value. For three of the HOX genes, (HOXA4, HOXA9, and HOXB4), the protein expression was also
determined using immunohistochemistry and an example of each staining from a single tumor is shown. Scale bar: 20 μm. Neg, negative – no primary
antibody. c HOXB4 tumor expression, as determined using quantitative real-time PCR, is significantly higher amongst patients surviving for less than
6 months after diagnosis (values on the y-axis are the ratio of HOXB4 to Beta-actin expression × 10000). d HOXB4 expression is associated with a shorter
overall survival. Kaplan-Meier survival curves for patients with high- and low-HOXB4 expressing tumors (p = 0.041). The cut-off point between high- and
low-expression was determined as the midpoint between the mean values of HOXB4 expression shown in (c), which was 53
NC
I-H
28
MS
TO
-2
11
NC
I-H
20
52
Me
t-5
A
NC
I-H
22
6
0
50
100
150
IC
50
 (
M
)
a b
c
0
20
40
60
80
100
120
0 50 100 150
Dose (uM)
%
 s
u
rv
iv
al NCI-H28 HX
NCI-H28 CX
Met-5A HX
Met-5A CX
***
***
**
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Fig. 3 HXR9 triggers apoptosis in treated cells. The mechanism of cell death was analyzed using a FACS-based Annexin / 7AAD method to assess early
and late apoptosis. a Sample dot plots for NCI-H28 cells treated with 18 μM HXR9 for 2 h. Viable cells sort to the lower left hand quadrant (low Annexin
/ 7AAD staining), whilst cells in early and late apoptosis sort to the lower and upper right hand quadrants, respectively. Necrotic cells are in the upper
left hand quadrant. b Apoptosis in NCI-H28 cells either untreated or incubated with 18 μM HXR9 or CXR9 for 2 h. The values are the means of three
experiments, error bars show the SEM. Treatment with HXR9 causes a significant increase in apoptosis (*, p < 0.05). c Summary of apoptosis data for all
five cell lines. V – viable cells, EA – cells in early apoptosis, LA – cells in late apoptosis, N-necrotic cells. The values are the means of three experiments,
error bars show the SEM. ***, p < 0.001; **, p < 0.01 relative to the corresponding values for Met-5a
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are the means of three experiments, error bars show the SEM. *** indicates a p < 0.001 compared to cFos expression in untreated cells. b Caspase
3 activation in NCI-H28 cells and Met-5A cells (c). The values are the means of three experiments, error bars show the SEM. * indicates a p < 0.05
compared to caspase 3 activity in untreated cells
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cFos in all of the cell lines, with the smallest increase in
Met-5A and the largest increase in the most sensitive
cell line, NCI-H28 (Fig. 4a). Correspondingly NCI-H28
also showed the greatest increase in Caspase 3 activity
(a protease involved in the apoptotic pathway; Fig. 4b),
whilst Met-5A failed to show any significant increase in
caspase activity (Fig. 4c).
Sensitivity to HXR9 correlates with the expression of
specific HOX genes
The expression of HOX genes with previously identi-
fied oncogenic or tumor suppressor properties
(Table 1; Fig. 1), raises the possibility that the
expression profile of these genes could determine the
sensitivity of cells to HXR9. To assess this we divided
HOX genes into two groups – those with potential
oncogenic functions, and those with possible tumor
suppressor functions. An expression ratio was ob-
tained by dividing the total expression of genes in the
former group with that in the latter (‘O/S ratio’). This
revealed that the most sensitive cell line, NCI-H28,
has the highest O/S ratio, whilst Met-5a and the least
sensitive malignant line, NCI-H226, have the lowest
O/S ratios (Fig. 5a). Plotting these ratios against the
IC50 for each cell line suggest a positive correlation
between the O/S ratio and sensitivity (Fig. 5b).
NC
I-H
28
MS
TO
-2
11
NC
I-H
20
52
Me
t-5
A
NC
I-H
22
6
0
1
2
3
4
5
O
/S
 r
at
io
***
***
+
18          28        45         98 107
IC50 ( M)  
a b
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Fig. 6 HXR9 blocks the growth of mesothelioma tumors in vivo. a The growth of MSTO-211H tumors in xenograft mice injected IP every 4 days
with PBS or 25 mg/Kg HXR9, for a total of five times. P values were calculated using a Student’s t-test for each time point, “*” indicates statistical
significance (p = 0.008, p = 0.037, and p = 0.041 for days 30, 34, and 37, respectively. b HOXB4 expression in the excised tumors from PBS-treated
mice, as determined by QRT-PCR. There was a linear relationship between tumor size and HOXB4 expression (r2 = 0.8278; p = 0.0321)
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Furthermore, the calculated O/S ratios for the pri-
mary mesothelium tumors indicate that these cells
could also be sensitive HXR9 (Fig. 5b).
HXR9 blocks the growth of mesothelioma tumors in vivo
In order to determine whether HXR9 could also block
tumor growth in vivo, we established a xenograft mouse
flank model using the MSTO-211H cell line. Mice were
injected IP with either PBS or 25 mg/Kg HXR9 in PBS
every 4 days after tumors had grown to a mean volume
of 100 mm3. HXR9 significantly retarded tumor growth
compared to PBS alone (Fig. 6a). In tumors from mice
injected with PBS only, we found a significant, linear re-
lationship between the expression of HOXB4 and final
tumor size (r2 = 0.8278; p = 0.0321; Fig. 6b).
Discussion
The dys-regulation of HOX genes in cancer is now well
established, and in many cases a putative function for indi-
vidual HOX genes has been established [20]. Despite a
high degree of sequence and regulatory conservation
between HOX genes, there is apparently a wide range of
cancer specific functions which include both oncogenic
and tumor suppressing activities. Thus for example the
fifth gene of the HOXA complex, HOXA5, acts primarily
as a tumor suppressor in breast cancer through stabilizing
p53 [9], whilst its closely related counterpart in the HOXB
cluster, HOXB5, can be defined as an oncogene as it can
immortalize fibroblast cells upon transfection [21].
None of these studies have as yet addressed whether
HOX genes are dys-regulated in mesothelioma, but here
we show that cell lines derived from mesothelioma as
well as primary mesothelioma cells have distinctly differ-
ent HOX expression patterns from the Met-5a cell line
that is derived from normal mesothelium. One of the
most striking differences is the expression of HOXC12
and HOXD12 by Met-5a but not by any of the meso-
thelioma cell lines. HOXC12 is repressed in follicular
lymphoma through hypermethylation of its promoter,
and has also been implicated in the differentiation of fol-
licle cells [22], both of which suggest a possible function
in tumor suppression. Likewise, the function of HOXD12
has not been defined, but it has been shown to be si-
lenced in melanoma cells through the methylation of its
promoter [23].
Another oncogenic HOX gene that we found to be up-
regulated in primary mesothelioma tumors was HOXB4.
High HOXB4 expression levels were associated with
shorter OS, suggesting that HOXB4 expression is a poten-
tial prognostic factor in this malignancy. We also found
that there was a positive, linear relationship between
HOXB4 expression and tumor growth in a mouse model
of human mesothelioma. Given the functional redundancy
amongst HOX proteins, this finding that HOXB4 was the
only HOX gene among the 39-strong family to have any
prognostic significance seems unexpected. However, there
are a number of other cancers for which a single HOX
gene alone acts as a prognostic marker, and the identity of
the HOX gene in each case varies from one malignancy to
another. Examples include HOXC6 in gastric cancer,
HOXB8 in ovarian cancer, and HOXD3 in breast cancer
[24]. This might reflect the embryonic origins of different
cancer types, as HOX gene expression in adult cells tends
to reflect their developmental origin [25]. From a practical
view point, there are currently no reliable markers of OS
in mesothelioma [26], and the use of HOXB4 as a prog-
nostic marker in this context therefore justifies further
evaluation.
In this study we have found that the ratio of expres-
sion between HOX genes with a putative oncogenic
function and those that have tumor suppressor activity
(‘O/S ratio’) predicts which mesothelioma cell lines are
most sensitive to HXR9, a peptide that prevents HOX
proteins binding to PBX and has been shown to cause
apoptosis in other malignancies [11–17]. The O/S ratio
may indicate the degree to which malignant cells are
dependent on the activity of oncogenic HOX genes for
their proliferation and survival, a concept similar to the
idea of ‘oncogene addiction’ [27], which would explain
their sensitivity to HXR9. The extent to which this is
true is yet to be determined, but at a more practical level
the O/S ratio might act as a biomarker for the sensitivity
of mesothelioma cells to HXR9, and could ultimately be
used to select patients that might benefit from this
therapeutic approach.
Conclusion
Our findings indicate that the HOX genes are widely
dysregulated and often strongly upregulated in meso-
thelioma, and that elevated HOXB4 expression predicts
shorter OS in mesothelioma patients. Targeting the
interaction between HOX proteins and their PBX cofac-
tor causes apoptosis in mesothelioma cells in vitro and
retards tumor growth in vivo, indicating that HOX pro-
teins are a potential therapeutic target in this
malignancy.
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